GlassScriptPhysician profile
Ryan Edwards Shaw
NPI 1760002448
$4,417.93
in general payments reported to CMS, 2019-2025
39 companies · $15.49 in 2025
The $15.49 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,407 · 2022: $1,556 · 2023: $1,267 · 2024: $172 · 2025: $15.49.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,454.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,454.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,303.03 | 2021-2025 | |
| Collegium Pharmaceutical, INC. | $464.04 | 2021-2023 | Xtampza |
| Avanir Pharmaceuticals, INC. | $237.54 | 2021-2022 | |
| Ucb, INC. | $236.41 | 2021-2023 | Briviact |
| Biohaven Pharmaceutical Holding Company LTD. | $219.73 | 2022 | |
| Scilex Pharmaceuticals INC. | $213.19 | 2021-2023 | Ztlido |
| Neurelis, INC. | $154.91 | 2021-2023 | Valtoco |
| Pfizer INC. | $151.24 | 2023-2024 | |
| Supernus Pharmaceuticals, INC. | $137.52 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $123.16 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $116.15 | 2021-2023 | Relistor |
| Genzyme Corporation | $111.49 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $102.25 | 2021-2023 | Austedo Xr |
| Novartis Pharmaceuticals Corporation | $82.90 | 2021-2024 | |
| Lilly USA, LLC | $80.63 | 2021-2022 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Shaw listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.